Oncimmune ONC bears witness to the world leading position which it is carving out for itself in medical technology. with the half year to the 30th November seeing excellent progress being made with its cancer detection technology which will detect cancers up to four years earlier than other methods and will do so by means of a simple blood test
The half year produced revenue of only £0.1m from early sales of its lung test kit but far more importantly for the future it took serious strides in establishing its technology and products in world markets.An exclusive distribution agreement and product development agreement was concluded in China, which included a minimum £10m. equity investment in the company plus a minimum £15.7m in royalties. Further agreements have been reached in twelve countries with minimum sales commitments amounting to £25.6m and in the US a preliminary distribution partnership has been entered into with a major US company. In the UK over 12,000 patients have been recruited for a lung cancer screening trial.
Liver test kits have commenced commercial sales and early lung cancer kits have received minimum payment guarantees of £7.9m over the next five years in the Asia Pacific region, excluding China, plus approximately £2m in Europe
TUI AG TUI has made a good start to the year with first quarter turnover rising by 8.1% and the net loss down from 81.6m to 58.7m. On an underlying like for like basis EBIT was up by 35.1% and net debt was halved. Expectations are that underlying EBITA growth for 2018 will be at least 10%.
RWS Holdings RWS The financial year to the end of September saw the fourteenth successive year of growth in sales, profits and dividends and RWS is confident of further substantial progress in 2018, when, despite currency headwinds in the US it aims to consolidate its global leading position in its chosen sectors. The integration of Monrovia which it acquired on the 3rd November will continue and the current financial year has started well.